Hagiwara A, Takahashi T, Lee R, Ueda T, Takeda M, Itoh T
Cancer. 1987 Jan 15;59(2):245-51. doi: 10.1002/1097-0142(19870115)59:2<245::aid-cncr2820590212>3.0.co;2-k.
A new drug dosage form comprising activated carbon particles adsorbing mitomycin C (MMC-CH) is designed to slowly release its components, and has affinity for the tumor surface and lymph nodes and a tendency to stay long in the local portion. The therapeutic index of MMC-CH in experimental carcinomatous peritonitis is 3.1 times as high as that of MMC-solution. In clinical experiments 81 patients with carcinomatous effusions were administered with MMC-CH (2.0-2.4 mg/kg in terms of MMC) in bolus intracavitarily. Fifty-one patients responded well to the MMC-CH therapy. Nineteen patients were alive for more than 6 months. The responders showed marked improvement in subjective symptoms, and 26 patients became dischargeable from hospital. Bone marrow suppression and peritoneal irritation were main adverse effects, but the symptoms were temporary and not so serious in spite of a high dose of MMC.
一种包含吸附丝裂霉素C的活性炭颗粒的新型药物剂型（MMC-CH）被设计用于缓慢释放其成分，对肿瘤表面和淋巴结具有亲和力，并倾向于在局部长期停留。MMC-CH在实验性癌性腹膜炎中的治疗指数是MMC溶液的3.1倍。在临床试验中，81例癌性积液患者接受了腔内大剂量注射MMC-CH（以MMC计为2.0-2.4mg/kg）。51例患者对MMC-CH治疗反应良好。19例患者存活超过6个月。反应者主观症状明显改善，26例患者可出院。骨髓抑制和腹膜刺激是主要的不良反应，但尽管使用了高剂量的MMC，症状是暂时的且不太严重。
